Inhaltsbereich
| 459 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 › » |
Seite 1 / 23
 Druckansicht
|
| Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. |
| Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G |
| Nature chemical biology. 2015 Jul 13. pii: nchembio.1859. doi: 10.1038/nchembio.1859. pmc: PMC4511833. mid: EMS63643 |
| PMID: 26167872 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. |
| Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G |
| Nature. 2014 Apr 2. pii: nature13194. doi: 10.1038/nature13194. pmc: PMC4150021. mid: EMS57294 |
| PMID: 24695225 |
| Markers of bone metabolism in premature myocardial infarction (≤ 40 years of age). |
| Goliasch G, Blessberger H, Azar D, Heinze G, Wojta J, Bieglmayer C, Wagner O, Schillinger M, Huber K, Maurer G, Haas M, Wiesbauer F |
| Bone. 2010 Nov 13. pii: S8756-3282(10)02036-3. doi: 10.1016/j.bone.2010.11.005 |
| PMID: 21078422 |
| Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. |
| Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hülsmann M, Niessner A |
| Atherosclerosis. 2010 Aug 19. pii: S0021-9150(10)00705-7. doi: 10.1016/j.atherosclerosis.2010.08.061 |
| PMID: 20843516 |
| In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. |
| Kastl SP, Speidl WS, Kaun C, Katsaros KM, Rega G, Afonyushkin T, Bochkov VN, Valent P, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J |
| Arteriosclerosis, thrombosis, and vascular biology. 2008 Jan 10. pii: ATVBAHA.107.160580. doi: 10.1161/ATVBAHA.107.160580 |
| PMID: 18187666 |
| Macrophage colony stimulating factor expression in human cardiac cells is upregulated by tumor necrosis factor-alpha via an NF-kappaB dependent mechanism. |
| Hohensinner PJ, Kaun C, Rychli K, Niessner A, Pfaffenberger S, Rega G, de Martin R, Maurer G, Ullrich R, Huber K, Wojta J |
| Journal of thrombosis and haemostasis : JTH. 2007 Oct 8. pii: JTH2784. doi: 10.1111/j.1538-7836.2007.02784.x |
| PMID: 17922812 |
| The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. |
| Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J |
| American journal of physiology. Heart and circulatory physiology. 2007 Jun 29. pii: 01366.2006. doi: 10.1152/ajpheart.01366.2006 |
| PMID: 17604327 |
| 13N-ammonia rest/stress PET: folic acid improves global coronary vasoreactivity in coronary artery disease patients with normal or elevated homocysteine levels. |
| Graf S, Nikfardjam M, Khorsand A, Ofluoglu S, Nekolla S, Dudczak R, Maurer G, Kletter K, Huber K, Pirich C |
| Nuklearmedizin. Nuclear medicine. 2006 Dec 6. pii: 06060248 |
| PMID: 17149493 |
| Idiopathic eosinophilic endomyocarditis in the absence of peripheral eosinophilia. |
| Priglinger U, Drach J, Ullrich R, Baumgartner H, Huber K, Maurer G |
| Leukemia & lymphoma. 2002 Mar 22. doi: 10.1080/10428190210184 |
| PMID: 11908733 |
| Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo. |
| Geiger M, Huber K, Wojta J, Stingl L, Espana F, Griffin JH, Binder BR |
| Blood. 1989 Aug 29. |
| PMID: 2752144 |
| Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. |
| Stojkovic S, Kaun C, Basilio J, Rauscher S, Hell L, Krychtiuk KA, Bonstingl C, de Martin R, Gröger M, Ay C, Holnthoner W, Eppel W, Neumayer C, Huk I, Huber K, Demyanets S, Wojta J |
| Scientific reports. 2016 May 4. pii: srep25171. doi: 10.1038/srep25171 |
| PMID: 27142573 |
| Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells. |
| Montanari E, Stojkovic S, Kaun C, Lemberger CE, de Martin R, Rauscher S, Gröger M, Maurer G, Neumayer C, Huk I, Huber K, Demyanets S, Wojta J |
| Thrombosis and haemostasis. 2016 May 12. pii: 15-12-0917. doi: 10.1160/TH15-12-0917 |
| PMID: 27173404 |
| Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. |
| Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G |
| Molecular cancer therapeutics. 2016 Nov 15. pii: 1535-7163.MCT-16-0235. doi: 10.1158/1535-7163.MCT-16-0235 |
| PMID: 28062706 |
| Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro. |
| Krychtiuk KA, Kaun C, Hohensinner PJ, Stojkovic S, Seigner J, Kastl SP, Zuckermann A, Eppel W, Rauscher S, de Martin R, Maurer G, Huber K, Wojta J, Speidl WS |
| Vascular pharmacology. 2017 Feb 9. pii: S1537-1891(16)30284-1. doi: 10.1016/j.vph.2017.02.003 |
| PMID: 28192257 |
| Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. |
| Radic-Sarikas B, Halasz M, Huber KVM, Winter GE, Tsafou KP, Papamarkou T, Brunak S, Kolch W, Superti-Furga G |
| Scientific reports. 2017 Jun 8. doi: 10.1038/s41598-017-03129-6. pii: 10.1038/s41598-017-03129-6 |
| PMID: 28596528 |
| Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site. |
| Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P |
| Leukemia. 2017 Jul 31. pii: leu2017245. doi: 10.1038/leu.2017.245 |
| PMID: 28757617 |
| Novel Tenascin-C Haplotype Modifies the Risk for a Failure to Heal After Rotator Cuff Repair. |
| Kluger R, Huber KR, Seely PG, Berger CE, Frommlet F |
| The American journal of sports medicine. 2017 Sep 1. doi: 10.1177/0363546517729810 |
| PMID: 28952802 |
| Predictive value of low interleukin-33 in critically ill patients. |
| Krychtiuk KA, Stojkovic S, Lenz M, Brekalo M, Huber K, Wojta J, Heinz G, Demyanets S, Speidl WS |
| Cytokine. 2017 Sep 30. pii: S1043-4666(17)30274-0. doi: 10.1016/j.cyto.2017.09.017 |
| PMID: 28974430 |
| In-Hospital Outcome Comparing Bivalirudin to Heparin in Real-World Primary Percutaneous Coronary Intervention. |
| Hasun M, Dörler J, Edlinger M, Alber H, Von Lewinski D, Eber B, Roithinger FX, Berger R, Siostrzonek P, Grimm G, Benzer W, Wintersteller W, Huber K, Schuchlenz H, Weidinger F |
| The American journal of cardiology. 2017 Sep 20. pii: S0002-9149(17)31456-X. doi: 10.1016/j.amjcard.2017.08.037 |
| PMID: 29103603 |
| 459 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 › » |
Seite 1 / 23
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
